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ABSTRACT 
The aim of present investigation was formulation and evaluation of mucoadhesive buccal tablet of Repaglinide to study the effect of different 
polymers on release profile of drug for prolonged release. In this study mucoadhesive buccal tablet were prepared by direct compression 
method. Various rheological characteristics of the powder bed like bulk density, compressibility index, and angle of repose w ere evaluated and 
studied. Mucoadhesive buccal tablets were compressed on a 8 station mini press using 10 mm flat faced punches and were all assessed for 
weight variation, hardness, thickness, percent swelling index, mucoadhesive strength and in vitro release of the drug by using USP TDT 08L 
dissolution testing apparatus method II using a paddle at 50 rpm. Data was optimized by using 32 full factorial design by using software named 
as design expert and with the help of kinetic study. The stability studies showed that there is no decrease in the drug content of all formulations 
for the period of 2 months. 
Keywords: Buccal tablet, Repaglinide, HPMC K100M, Xanthan gum. 
 
Article Info: Received 10 July 2019;     Review Completed 17 Aug 2019;     Accepted 23 Aug 2019;     Available online 30 Aug 2019 
Cite this article as: 
Thakare EB., Malpure PS., Maru AD., More YM, Formulation and Evaluation of Mucoadhesive Buccal Tablet of Repaglinide, 
Journal of Drug Delivery and Therapeutics. 2019; 9(4-A):415-424  http://dx.doi.org/10.22270/jddt.v9i4-A.3488                                                               
*Address for Correspondence:  
Mr. Thakare Eknath B., Department of Pharmaceutics, Loknete Dr. J.D. Pawar College of Pharmacy, Manur, Tal-Kalwan, 
Dist-Nashik (Maharashtra) 423501 
 
 
INTRODUCTION 
Bioadhesion can be defined as a phenomenon of 
interfacial molecular attractive forces in the midst of the 
surfaces of biological substrate and the natural or synthetic 
polymers, which allows the polymer to adhere biological 
surface for an extended period of time. Among the various 
routes of drug delivery the oral route is perhaps the most 
preferred by patients and clinicians alike. However, peroral 
administration of drugs has disadvantages, such as hepatic 
first-pass metabolism and enzymatic degradation within the 
gastrointestinal (GI) tract, that prohibit oral administration 
of certain classes of drugs, especially peptides and proteins. 
Consequently, other absorptive mucosas are considered as 
potential sites for drug administration. Transmucosal routes 
of drug delivery (i.e., the mucosal linings of the nasal, rectal, 
vaginal, ocular, and oral cavities) offer distinct advantages 
over peroral administration for systemic effect. These 
advantages include possible bypass of first-pass effects and 
avoidance of presystemic elimination within the GI tract.  
The buccal region of oral cavity is an attractive site 
for the delivery of drugs owing to the ease of the 
administration. Buccal drug delivery involves the 
administration of desired drug through the buccal mucosal 
membrane lining of the oral cavity. This route is useful for 
mucosal (local effect) and trans-mucosal (systemic effect) 
drug administration. In the first case, the aim is to achieve a 
site-specific release of the drug on the mucosa, where as the 
second case involves drug absorption through the mucosal 
barrier to reach the systemic circulation.  
Mucoadhesive drug delivery systems 
Mucoadhesive drug delivery systems are delivery 
systems, which utilized the property of bioadhesion of 
certain polymers, which become adhesive on hydration and 
hence can be used for targeting a drug to particular region of 
the body for extended period of time. The ability to maintain 
a delivery system at a particular location for an extended 
period of time has great appeal for both local as well as 
systemic drug bioavailability. Pharmaceutical aspects of 
mucoadhesion have been the subject of great interest during 
recent years because it provides the possibility of avoiding 
either destruction by gastrointestinal contents or hepatic 
first-pass in activation of drug.  
MATERIALS &METHODS 
Materials 
Repaglinide was provided as sample from 
Swapnroop Laboratories Aurangabad. HPMC K100M, 
Chitosan, dextrose, mannitol, ethyl cellulose. 
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Ingredient used in formulation  
Table1: Ingredient used in formulation. 
Sr. No Name of 
ingredients 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Repaglinide 10 10 10 10 10 10 10 10 10 
2 HPMC K 100 M 15 15 15 20 20 20 25 25 25 
3 Chitosan 15 20 25 15 20 25 15 20 25 
5 Dextrose 35 35 35 35 35 35 35 35 35 
6 Mannitol 25 20 15 20 15 10 15 10 5 
7 Ethyl cellulose 100 100 100 100 100 100 100 100 100 
 
Preformulation studies 
Preformulation studies on the obtained sample of 
drug for identification and compatibility studies were 
performed 
Characterization of the Drug  
Organoleptic properties  
The sample of Repaglinide was studied for 
organoleptic properties such as colour, odour and 
appearance. 
Melting point  
The melting points of Repaglinide were determined 
by melting point apparatus. Observed value was compared 
with the reported value. 
Drug excipient compatibility study 
Drug excipient compatibility was performed by 
liquid Fourier Transform infrared. It was performed by 
mixing drug with excipient in equal proportion and then IR 
spectrum was noted for mixture using NaCl cell. Small 
amount of the mixture was placed on the sample cell, the cell 
was then filtered in sample holder, spectra were scanned 
over a frequency range 4000-400cm-1 with FTIR instrument 
and the spectral analysis were done.  
Preparation of Mucoadhesive buccal tablet (By Direct 
compression method)  
1. Weighing of ingredients  
2. Milling of drug and Excipients  
3. Mixing of drug and Excipients  
4. Tablet compression  
EVALUATION OF MUCOADHESIVE BUCCAL TABLETS 
Hardness test  
Hardness test was conducted for three tablets from 
each batch and average values were calculated. 
Weight variation test 
Weight variation test was performed for ten tablets 
from each batch using an electronic balance and average 
values were calculated. 
Table 2: Percentage deviation in weight variation 
Average weight of a tablet Percentage deviation 
130 mg or less 10 
More than 130 mg and less 
than 324 mg 
7.5 
324 mg or more 5 
 
Thickness 
The thicknesses of buccal tablets were determined 
using digital micrometer (Digital Caliper, Aerospace, India). 
Ten individual tablets from each batch were used and the 
average thickness was calculated. 
Friability test 
Friability of twenty randomly selected tablets from 
each formulation were determined by using the Roche type 
friabilator. 
In vitro drug release for Repaglinide tablet 
The drug release profile was studied using USP 
dissolution testing apparatus method II using a paddle at 50 
rpm 900ml dissolution fluid, pH 6.8 phosphate buffer, was 
used and a temperature of 37 ±0.5°C was maintained. 5ml 
aliquots at 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 11h, 12 h 
respectively were pipette out and the same volume was 
replaced with pH 6.8 phosphate buffer. Absorbance was 
measured at λmax282nm and from which percentage of 
Repaglinide was calculated using calibration curve.
 
Table 3: In vitro drug release studies details 
Apparatus used USP Type II dissolution test apparatus 
Dissolution medium Phosphate buffer pH 6.8 
Dissolution medium volume 900 ml 
Temperature 37 0.5°c 
Speed of basket 50 rpm 
Sampling intervals 1 Hrs 
Sample withdraw 5 ml 
Absorbance measured 282 nm 
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In vitro mucoadhesive strength 
In vitro mucoadhesive strength of tablet was 
measured with goat Oral mucosa, using a modified physical 
balance. On one side of the balance, a rubber closure tied 
with thread was attached and on other side empty polythene 
bag was attached. Goat oral mucosa was obtained from a 
local slaughter house and stored in a phosphate buffer pH 
6.8 upon collection. The experiments were performed within 
3 h of collection of oral mucosa which has been separated 
from sheep stomach. The goat stomach mucosa was fixed to 
the opening of the glass vial with thread and then placed in a 
beaker, well packed. Phosphate buffer pH 6.8 was added into 
the beaker up to the upper surface of the buccal mucosa to 
maintained oral mucosal viability during the experiment. 
The tablet was sticked to the rubber closure with 
cyanoacrylate glue, then the beaker was raised slowly until 
contact between goat oral mucosa and tablet was 
established. A preload of 5 gm was placed on the clamp for 5 
min (preload time) to establish adhesion bonding between 
tablet and goat oral mucosa. The preload time were kept 
constant for all the formulations. After completion of the 
preload time, preload was removed from the clamp and 
water was then added in the polythene bag by pipette in 
drop-wise manner, at a constant rate. The weight of water 
required to detach tablet from stomach mucosa was noted as 
in vitro mucoadhesive strength, and these experiments were 
repeated with fresh mucosa in an identical manner. The 
modified physical balance for in vitro mucoadhesive strength 
determination consisting of polythene bag (on one side) and 
rubber closure for attachment of tablet (on other side). 
 
Swelling Study 
Buccal tablet are weighed individually (W1) and 
placed separately in petri dishes containing phosphate 
buffer pH 6.8 for 8 hrs at regular interval of time (1, 2, 4, 6 
and 8 hr) and  The tablet are removed from the petri dishes 
and excess surface water is removed using filter paper. The 
tablet are weighed (W2) and swelling index (SI) is calculated 
as follows 
SI = (W2-W1)/W1 
Drug content uniformity 
 Ten tablets were accurately weighed and powder 
crushed in a glass pestle mortar. An accurately weighed 
amount equivalent to 5 mg of pure drug was taken, and the 
assay was performed UV spectrophotometer. 
Optimization by 32 factorial designs:  
Optimization is the key parameter in the 
development of any product factorial designs used to 
evaluate two or more factors simultaneously interactions 
can be determined in the factorial design. A study in which 
two factors and three levels are involved is called as 32 
factorial design. For the present work 32 factorial design  
selected and 2 factors were evaluated at three possible 
levels by formulating all possible 9 formulation combination 
which are shown in table 3.                                                      
Formulation code assigned to the batches  
X1=   HPMC K100M 
X2=   Xanthan gum 
 
Table 4: design summary. 
Factor  Name  Unit  Type  Min. Max. -1 
actual  
+1 
actual  
Mean  Std. 
Dev. 
A HPMC K100M % Numeric  15 25 -1.00 1.00 40 12.18 
B Xanthan Gum % Numeric  15 25 -1.00 1.00 40 12.18 
 
HPMC K100M and Chitosan are independent variable used in 
the formulation. They are mucoadhesive polymer to increase 
the residence time of formulation in oral cavity and also 
show their effect on mucoadhesive strength, swelling index, 
in vitro drug release.  
Independent variable  
X1= HPMC K100M  
X2= Xanthan gum 
Dependent variable  
Y1= Drug release  
Y2= Swelling index  
Y3= Mucoadhesive strength 
In- Vitro Drug Release Kinetic Study 
Zero Order Kinetics 
A Zero order release would be predicted by the following 
equation, 
Qt-Q0=K0t 
Where 
Qt =Amount of drug release dissolved in time ‘t’ 
Co=Initial amount of drug concentration in solution. 
Kot=Zero order rate constant. 
When the data were plotted as cumulative % drug release 
versus time, if the plot is linear then data obeys zero order 
kinetics with slope equal to K0. This model represents an 
ideal release profile in order to achieve the prolonged 
pharmacological action. 
First Order Kinetics: 
A first order release would be predicted by the following 
equation 
Log Qt=Log Q0-Klt/2.303 
Where, 
Qt=Amount of drug released in time ‘t’ 
Co=Initial amount of drug concentration in solution. 
Klt=first order rate constant 
When data were plotted as log cumulative% drug remaining 
versus time yields a straight line indicating that the release 
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follows first order kinetics. The constant K can be obtained 
multiplying slope values. 
Higuchi’s Model: 
Drug release from the matrix device by diffusion has been 
described by Higuchi’s diffusion equation 
Ft=Q=VD5/T(2C-5Cs)Cst 
Where, 
Q=Amount of drug release dissolved in time‘t’. 
Co=diffusion coefficient of drug in the release matrix. 
Cs=Solubility of drug in the matrix. 
5=porosity of matrix 
t=Tortuosity 
T=Time (h) 
The equation may be simplified then the equation becomes, 
Ft=Q=KhX t1/2 
Where, 
Kh=Higuchi dissolution constant 
When data were plotted according to this equation, i.e. 
cumulative drug released versus square root of time, yields a 
straight line, indicating that the drug was released by 
diffusion mechanism. 
PeppasKorsmeyer Equation 
In 1983 korsmeyeret. al developed a simple, semiempirical 
model,when diffusion is the main drug release mechanism, 
relating exponentially the drug release to the elapsed time 
(t) 
At/Ao=Kt/n 
Where, 
K=Constant 
n=Release 
t=Time 
At and Ao=Absolute cumulative amount of drug released at 
times. 
This is used when the release mechanism is not well known 
or when more than one type of a release phenomenon could 
be involved. 
RESULT AND DISCUSSION 
Preformulation study 
Identification and Characterization of the Drug 
Organoleptic Properties 
The organoleptic properties of Repaglinide such as 
colour, appearance, odour was observed visually 
 
Table 5: Identification tests of Repaglinide  
Parameter Reported value Observed value 
Appearance Crystalline Crystalline 
Colour White White 
Odour Odourless Odourless 
 
 
Melting Point 
The melting point was determined by melting point apparatus and the melting point was found to be 
Table 6: Melting point of Repaglinide  
Parameter Standard Observed 
Melting Point 130-1310   C  128-1320 C  
 
 
Solubility 
Solubility of Repaglinide was checked in various solvents 
Table 7: Determination of drug solubility in various solvents 
Sr. No. Solvent Descriptive term 
1 Methanol Soluble 
2 Water Insoluble 
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DRUG EXCIPIENTS COMPATABILITY STUDY 
Infra red spectrum 
The FTIR spectrum of pure Repaglinide showed peaks in wave numbers (cm-1) which corresponds to the functional 
group present in the structure of the drug. FT-IR spectrum of Repaglinide is shown in figure 1.  
 
Figure 1: FT-IR Spectrum of Repaglinide. 
Fourier transform infra-red spectroscopy (FTIR) 
Infra-red spectra of drug and polymers showed matching peck with the drug spectra. The data obtained from the IR 
spectra showed no evidence of the interaction between the drug and the polymer studies. All the major characteristics pecks of 
the drug were present in the drug polymer combination spectra which indicate compatibility of drug with the polymers. 
Drug + HPMC K100M 
 
Figure 2:  FTIR Spectrum of Drug + HPMC K100M 
Drug + Chitosan 
 
Figure 3: FTIR Spectrum of Drug + Chitosan Mixture 
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Differential Scanning Calorimetry 
Thermal analysis of drug was carried out using DSC. The Differential Scanning Calorimetry curve of repaglinide profiles a sharp 
exothermic peak at 1340 C corresponding to its melting, and indicating its crystalline nature and purity of sample.  The DSC 
thermogram is shown in Figure 4. 
 
Figure 4: DSC Thermogram of Repaglinide 
PRE-COMPRESSION PARAMETERS 
Table 8: Pre compression parameters for Mucoadhesive buccal tablet 
Formulation 
code 
Angle of repose (0)  
Mean ±S.D* 
Bulk density(g/ml)  
Mean ±S.D* 
Tapped density 
(g/ml)  Mean ±S.D* 
Carr’s index 
(%) Mean ±S.D* 
Hausner’s ratio  
Mean ±S.D* 
F1 33.97±1.71 0.39±0.015 0.45±0.015 13.33±1.45 1.15±0.020 
F2 34.59±0.79 0.38±0.010 0.43±0.010 11.62±1.45 1.10±0.013 
F3 33.40± 0.86 0.36±0.005 0.41±0.010 12.19±0.94 1.13±0.011 
F4 30.46 ±0.83 0.37±0.006 0.41±0.016 09.75±1.63 1.10±0.008 
F5 30.71±0.68 0.37±0.011 0.42±0.016 11.24±1.67 1.12±0.012 
F6 32.82±1.05 0.38±0.008 0.42±0.008 09.52±1.28 1.10±0.016 
F7 29.74±1.03 0.37±0.009 0.42±0.008 11.90±0.86 1.13±0.021 
F8 31.47±0.98 0.37±0.010 0.43±0.009 13.95±1.50 1.16±0.020 
F9 31.76 ±1.22 0.38±0.013 0.44±0.010 13.63±0.99 1.15±0.015 
*n=6 
POST COMPRESSION PARAMETERS 
Table 9: Post compression parameters for Mucoadhesive buccal tablet 
Formulation 
code 
Hardness 
(Kg/cm2)* 
Thickness 
(mm)* 
Friability 
(%)* 
Weight variation 
(mg)* 
pH* 
F1 5.9±0.11 3.21±0.011 0.89±0.023 248±1.04 6.8±0.09 
F2 5.8±0.12 3.25±0.010 0.82±0.014 252±1.41 6.6±0.11 
F3 5.6±0.10 3.22±0.008 0.40±0.017 247±1.47 6.7±0.08 
F4 5.5±0.12 3.20±0.014 0.40±0.034 253±1.04 6.6±0.10 
F5 5.8±0.10 3.25±0.011 0.60±0.029 250±1.94 6.8±0.11 
F6 6.0 ±0.11 3.20±0.011 0.40±0.021 248±1.47 6.7±0.14 
F7 6.0±0.14 3.24±0.021 0.56±0.026 250±1.72 6.8±0.12 
F8 5.7±0.14 3.21±0.011 0.44±0.014 247±1.41 6.8±0.10 
F9 5.9±0.13 3.19±0.011 0.40±0.026 246±1.60 6.7±0.08 
 
Drug content 
 
Figure 5: Graphical presentation of drug content 
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Swelling study 
 The swelling index of Repaglinide buccal tablet for 8 hrs. The water uptake nature of the polymer is one of the important 
properties that affect the onset of swelling. Swelling index increases with increases concentration of the HPMC K100M and 
xanthan gum. The formulation F7 possessing highest swelling index. 
 
 
Figure 6:  Graphical Presentation of swelling index 
 
Mucoadhesive strength  
   The highest bioadhesion strength was possessed 
by the formulation containing HPMC K 100 M and Xanthan 
gum. Increases in the concentration of HPMC K100 M and 
Xanthan gum increases bioadhesion strength of the 
formulation. 
 
Figure 7: Graphical presentation of Mucoadhesive 
strength 
In-vitro dissolution study 
In -Vitro drug Release Studies of Repaglinide 
buccal tablets were determined using USP type II apparatus. 
The drug release was found to vary according to the ratio of 
mucoadhesive polymers. The formulation F7 showed the 
optimum drug release 96.21% at the end of 12 hrs 
containing HPMC K100M and xanthan gum. 
 
 
 
 
Figure 8:  Graphical presentation of In-vitro drug release 
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Figure 9:  Graphical presentation of In-vitro drug release 
Optimization 
A 32 full factorial design was selected and 2 factors 
were evaluated at 2 levels, respectively. The percentage of 
HPMC K100M (X1) and Xanthan Gum (X2) were selected as 
independent variables and dependent variables drug 
release, swelling index, mucoadhesive strength. The data 
obtain were treated using design expert software and 
analyzed statistically using analysis of variance (ANOVA). 
 
Figure 10: surface response plot showing effect of HPMC 
K100M and Xanthan Gum on drug release 
 
Figure 11: Counter plot showing effect of HPMC K100M 
and Xanthan Gum on drug release 
 
Figure 12:  surface response plot showing effect of HPMC 
K100M and Xanthan Gum on swelling index 
 
Figure 13: Counter plot showing effect of HPMC K100M 
and Xanthan Gum on swelling index 
 
Figure 14:  surface response plot showing effect HPMC 
K100M and Xanthan Gum on mucoadhesive strength 
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Figure 15: Counter plot showing effect of HPMC K100M and Xanthan Gum on mucoadhesive strength 
 
From design expert optimum batch of HPMC K100M and Xanthan Gum was found to be optimized. From this data F7 was 
selected as optimized formulation. 
Kinetic Study 
In the present study, the drug released mechanism from all formulation and evaluation of mucoadhesive tablet formulation 
different kinetic models was analyzed using factorial design batches followed zero order , first order model kinetic, Highuchi 
and Korsemeyer’s Peppas model kinetics. 
Table 10:  R2 values of Korsemayer’s peppas model kinetics 
Batch F1 F2 F3 F4 F5 F6 F7 F8 F9 
R2 0.923 0.994 0.914 0.909 0.925 0.986 0.939 0.967 0.979 
N  Value 0.523 0.562 0.589 0.526 0.549 0.563 0.578 0.512 0.545 
 
The classical zero order released curved was found to be linear the curve plotted according to first order and Highuchi were 
also found to be linear respectively. For the Korsemeyer’s Peppas released curves r2 was found to be ≥ 0.90 for all formulation 
and n value was found to be ≥ 0.5 which indicate that all the formulation show anomalous or non-fickian diffusion. The drug 
release occurs probably by diffusion, erosion and dissolution follows. 
Stability studies of Mucoadhesive buccal tablet of Repaglinide 
Table 11: Stability study of optimized formulation 
Sr .No. Observations Before Stability 
Stability testing interval days 
1 months 2 months 
1. 
General appearance    
Color No change No change No change 
Odor No change No change No change 
2. Ph 6.4 6.5 6.4 
3. % Drug release 96.35 96.15 95.80 
4. % Drug content 96.50 97.05 96.87 
 
Optimized formulation F7 at 25 0c temperature was found to be stable up to 2 months. There was no significant change in 
appearance, drug release and drug content. 
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CONCLUSION 
It was planned in this investigation to formulate and 
evaluate mucoadhesive buccal tablet of Repaglinide to 
release the drug in buccal cavity for extended period of time 
in order to avoid first pass metabolism to reduce the dosing 
frequency and to improve the patient compliant. 
Experiments were conducted to investigate the influence of 
polymer like  HPMC K100M and xanthan gum bioadhesion 
strength and release kinetic of mucoadhesive tablet of 
Repaglinide. In vitro dissolution studies were conducted in 
apparatus II at 50 rpm for 12 hr. Drug content of all 
formulation were found to be more than 96.55%. The pH of 
all mucoadhesive formulation was in between 6.7 to 6.8. In 
vitro drug release result of all the formulation were 
conducted for 12 hrs of all tablet formulation F1 -F9. The 
formulations F7  were taken as an optimized batch. It can be 
seen that by increasing the concentration of  HPMC K100M 
and xanthan gum in the formulation, the drug release rate 
was found to be increased. The in vitro release kinetic 
indicate that all the formulation show anomalous or non-
fickian diffusion. The drug release occurs probably by 
diffusion, erosion and dissolution follows. The data was 
statically analyzed and mechanism of release kinetic studied. 
All the studies were conducted at least 6 times and average 
was computed and tabulated. 
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